How do I check that two TFC lots of oral semaglutide agree on content assay?

Conditions: TFC · oral semaglutide.

I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact.

I want to know whether this is recoverable or whether the honest answer is to write it off.

Is this recoverable, and how would I tell?

It helps to be literal here: a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Assume segregation is possible, and design your sampling to catch it if it exists.

Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 3 May 2025 by coldbox9 — updated for the 2026 guidance change

Put another way, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

On the detail: most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 3 May 2025 by fibre_or_fragment — tightened the wording; no substantive change